Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.65 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.55 |
| ▸ | FPR2 | P25090 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23453711 | 0.94 | GPR119 (0.60) | GPR119CHEK2FPR2FAAH | |
| SCHEMBL7318758 | 0.93 | GPR119 (0.74) | GPR119CHEK2FPR2FAAH | |
| SCHEMBL13335340 | 0.89 | GPR119 (0.70) | GPR119CHEK2FAAH | |
| SCHEMBL2456170 | 0.89 | GPR119 (0.57) | GPR119CHEK2FPR2 | |
| SCHEMBL4322579 | 0.88 | GPR119 (0.65) | GPR119CHEK2FAAH | |
| SCHEMBL4159824 | 0.88 | GPR119 (0.65) | GPR119CHEK2 | |
| SCHEMBL2158159 | 0.88 | GPR119 (0.65) | GPR119CHEK2 | |
| SCHEMBL16385072 | 0.87 | GPR119 (0.67) | GPR119CHEK2 | |
| SCHEMBL22436046 | 0.86 | GPR119 (0.61) | GPR119CHEK2FAAH | |
| SCHEMBL1575603 | 0.86 | GPR119 (0.63) | GPR119CHEK2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026258-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2011-09-27 | — | — | US | disclosed |
| US-20100120845-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-05-13 | — | — | US | disclosed |
| US-7674805-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-03-09 | — | — | US | disclosed |
| US-20080312262-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-12-18 | — | — | US | disclosed |
| US-7439257-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2008-10-21 | — | — | US | disclosed |
| US-20070021424-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| WO-1994012181-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021424-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | CMBL, ALK, ALKBH1 | GPR119 1289/4885CHEK2 3685/4885FPR2 541/4885 |
| US-20100120845-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | CMBL, ALK, ALKBH1 | GPR119 1289/4885CHEK2 3685/4885FPR2 541/4885 |
| US-20080312262-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | CMBL, ALK, ALKBH1 | GPR119 1289/4885CHEK2 3685/4885FPR2 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.